Purchase this article with an account.
Sara Bozorg, Seanna Grob, G Hughes, Mark H. Nelson, Paul E. Tournambe, Michael H. Goldbaum, Henry A. Ferreyra, William R. Freeman, Igor Kozak, Kang Zhang; Genotypic Analysis Of Treatment Response To Anti-vegf Therapy In Age-related Macular Degeneration. Invest. Ophthalmol. Vis. Sci. 2011;52(14):5242.
Download citation file:
© ARVO (1962-2015); The Authors (2016-present)
To investigate whether genotype can help predict an individual’s response rate to anti-VEGF therapy in the setting of exudative age-related macular degeneration (AMD).
A retrospective chart review was performed on 264 patients treated with anti-VEGF for exudative AMD. Five single nucleotide polymorphisms (SNPs) - rs2274700 and rs1061170 in CFH, rs17611 in C5, rs2230199 in C3 and rs9332739 in C2 - were genotyped using the SNaPshot method. Visual acuity and spectral domain optical coherence tomography (SD-OCT) were used to determine clinical response. The patients were considered non-responders to anti-VEGF therapy if their visual acuity did not improve by 1 ETDRS line or if their foveal thickness did not decrease as a result of therapy. Chi-squared tests were used for analysis of genetic data.
We reviewed the data of 264 patients treated with anti-VEGF for exudative AMD. Of these, 112 patients were found to be responders to anti-VEGF and 152 patients were considered non-responders. There was no statistically significant correlation with responsiveness to anti-VEGF therapy and the presence of at risk or protective AMD alleles in the genetic variants tested.
Candidate risk or protective alleles for AMD were not associated with treatment response. Further studies on more candidate genes and a genome wide study will aid identification of the genetic underpinnings in anti-VEGF response and maximize patient benefit through personalized medicine.
This PDF is available to Subscribers Only